However, Yang P et al. 57 found that the presence of TERT promoter mutation in WHO II and III gliomas means a good outcome, and it has been an independent factor relevant to a good prognosis in the IDH mutation (IDH-mut) subgroup. This evidence concerns the gene IDH1 and central nervous system cancer.